Objective B-cell activating factor (BAFF) is essential for B-cell survival and innate immune activation, and its ...
Background Cardiovascular disease and osteoarthritis (OA) share risk factors, but the link between comprehensive ...
Background Management of systemic lupus erythematosus (SLE) is largely guided by organ involvement. Serositis affects up to 46% of patients, yet its treatment is mainly empirical and extrapolated from ...
Objectives To evaluate the long-term outcomes, clinical phenotypes and factors associated with complications in Still’s ...
Background Patients with psoriasis (PsO) are at increased risk of developing psoriatic arthritis (PsA). Emerging evidence ...
Objectives Owing to the underrepresentation of early-stage disease in randomised trials and inconsistent clinical evidence, ...
Objectives Nerandomilast, a selective phosphodiesterase 4B (PDE4B) inhibitor, has been extensively investigated for the treatment of pulmonary fibrosis; however, its therapeutic potential and ...
Objectives Smoking is recognised as one of the strongest environmental risk factors for the development of rheumatoid ...
Over the last decade, the outlook for patients with rheumatoid arthritis (RA) has improved, but there is growing interest in ...
Objective Methylprednisolone pulses (MP) help achieve prolonged remission in patients with moderate–severe systemic lupus erythematosus (SLE), but their potential effect in reducing damage accrual has ...
Objectives Current therapeutic paradigms for treatment-refractory rheumatic diseases rely on chronic immunosuppression with variable efficacy and potential for cumulative toxicity. We systematically ...
Objective To develop and validate a predictive model for distinguishing controls (Ctr), rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) based on nailfold videocapillaroscopy (NVC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results